Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Gets Price Target Increase from Wells Fargo & Company

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its target price hoisted by Wells Fargo & Company from $87.00 to $110.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective indicates a potential upside of 23.32% from the company’s previous close.

A number of other research analysts also recently weighed in on KNSA. Canaccord Genuity Group lifted their price target on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. JPMorgan Chase & Co. increased their price objective on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. The Goldman Sachs Group raised their price objective on Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Citigroup lifted their target price on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Finally, Weiss Ratings raised shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $96.43.

Kiniksa Pharmaceuticals International Stock Up 22.2%

KNSA stock opened at $89.20 on Wednesday. Kiniksa Pharmaceuticals International has a one year low of $35.20 and a one year high of $90.80. The firm has a 50-day moving average of $78.23 and a two-hundred day moving average of $59.23.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.19. The firm had revenue of $285.97 million during the quarter, compared to analysts’ expectations of $260.66 million. As a group, equities research analysts predict that Kiniksa Pharmaceuticals International will post 1.37 earnings per share for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, CAO Michael Megna sold 4,600 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total value of $369,380.00. Following the transaction, the chief accounting officer directly owned 29,062 shares of the company’s stock, valued at approximately $2,333,678.60. This trade represents a 13.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 51.98% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Rubric Capital Management LP boosted its holdings in Kiniksa Pharmaceuticals International by 12.7% during the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock valued at $180,562,000 after acquiring an additional 421,347 shares during the period. Dimensional Fund Advisors LP increased its position in Kiniksa Pharmaceuticals International by 18.8% during the first quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock worth $39,086,000 after acquiring an additional 128,417 shares during the period. Spruce Street Capital LP raised its position in shares of Kiniksa Pharmaceuticals International by 75.0% during the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock valued at $36,645,000 after buying an additional 326,081 shares during the last quarter. Bank of America Corp DE raised its position in shares of Kiniksa Pharmaceuticals International by 220.9% during the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after buying an additional 506,576 shares during the last quarter. Finally, Rice Hall James & Associates LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 2.0% in the first quarter. Rice Hall James & Associates LLC now owns 608,416 shares of the company’s stock valued at $29,295,000 after buying an additional 11,985 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Key Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Quarterly results exceeded expectations. Kiniksa reported third-quarter adjusted earnings of $0.56 per share, up from $0.23 a year earlier and above analyst estimates of approximately $0.32-$0.37. Revenue reached $285.97 million, surpassing the roughly $260.66 million consensus estimate. Kiniksa Pharmaceuticals International Reports Third-Quarter and Nine-Month Earnings
• Positive Sentiment: ARCALYST sales continued to accelerate. Net product revenue rose approximately 58% year over year to $286 million. The company said ARCALYST penetration among patients with multiple recurrences of pericarditis reached 23%, indicating additional room for growth in the core market. Kiniksa Pharmaceuticals: Three Key Takeaways for Long-Term Investors
• Positive Sentiment: Management raised its 2026 outlook. Expected ARCALYST revenue was increased to $1.045 billion-$1.050 billion, or more than $1.045 billion, reinforcing expectations for continued commercial momentum. Kiniksa Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Pipeline progress adds longer-term potential. Kiniksa expects pivotal Phase 3 data for KPL-387 in the second half of 2027, offering a future catalyst beyond ARCALYST’s current growth. Kiniksa Q3 2026 Earnings Call Transcript
• Neutral Sentiment: Short-interest data showed no reported short position. A report listed October short interest at zero shares and a zero-day days-to-cover ratio. While this does not indicate active bearish positioning, the figure may reflect incomplete or unusual data rather than a meaningful fundamental development.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.